Jan 24, 2024
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
Jan 23, 2024
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Congenital hyperinsulinism (CHI) is a rare genetic disease that presents very early in life and is characterized by excess and erratic insulin secretion that can cause infants, children, and adults to become dangerously hypoglycemic and starve their bodies of glucose.
Diabetic Macular Edema (DME) is a disease associated with diabetes, when chronic excess glucose in the blood stream can cause inflammation and breakdown of the body’s blood vessels, including at the back of the eye where fluid may leak into the retina. DME is the leading cause of blindness in the US and elsewhere.
Tumor-associated hyperinsulinism (taHI) occurs when pancreatic neuroendocrine tumors (i.e. “insulinomas”) over-produce insulin, resulting in excessive insulin receptor activation and hypoglycemia. Insulinomas are the most common type of functional pancreatic neuroendocrine tumor, affecting 10,000-15,000 patients in the US, of which ~10 percent have malignant/unresectable tumors requiring chronic medical therapies to directly to control their hypoglycemia.
At REZOLUTE, we are driven to develop novel therapies that boldly transform the treatment paradigm for debilitating diseases with significant unmet needs. We listen to the patient and the community to guide and inform our approach on bringing forward therapeutics that can make a difference. As parents, patients, and caregivers, the spectrum of our humanity informs and inspires everything we do in our mission to develop life-changing therapies. We are REZOLUTE in our commitment to restore balance to life.
A world where days are defined by special moments and balance is restored to the lives of patients and their families.